{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:52:26Z","timestamp":1791071546505,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01610-y","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:50:48Z","timestamp":1791024648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fibrolamellar Carcinoma in the Molecular Era: From DNAJB1::PRKACA Biology to Precision Therapeutic Strategies"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7336-4647","authenticated-orcid":false,"given":"Tuba","family":"Bayda\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lker Nihat","family":"\u00d6kten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"6174","key":"1610_CR1","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1249484","volume":"343","author":"JN Honeyman","year":"2014","unstructured":"Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim IIP, Gleason CE, Murphy JM, Rosenberg BR, Teegan L, Takacs CN, Botero S, Belote R, Germer S, Emde AK, Vacic V, Bhanot U, LaQuaglia MP, Simon SM. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014;343(6174):1010\u20134. https:\/\/doi.org\/10.1126\/science.1249484.","journal-title":"Science"},{"issue":"11","key":"1610_CR2","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1038\/s41375-021-01436-6","volume":"35","author":"EA Bruford","year":"2021","unstructured":"Bruford EA, Antonescu CR, Carroll AJ, et al. HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. Leukemia. 2021;35(11):3040\u20133. https:\/\/doi.org\/10.1038\/s41375-021-01436-6.","journal-title":"Leukemia"},{"issue":"6","key":"1610_CR3","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1053\/j.gastro.2017.09.008","volume":"153","author":"LH Engelholm","year":"2017","unstructured":"Engelholm LH, Riaz A, Serra D, Dagnaes-Hansen F, Johansen JV, Santoni-Rugiu E, Hansen SH, Niola F, Frodin M. CRISPR\/Cas9 engineering of adult mouse liver demonstrates that the Dnajb1-Prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma. Gastroenterology. 2017;153(6):1662\u2013e167310. https:\/\/doi.org\/10.1053\/j.gastro.2017.09.008.","journal-title":"Gastroenterology"},{"issue":"50","key":"1610_CR4","doi-asserted-by":"publisher","first-page":"13076","DOI":"10.1073\/pnas.1716483114","volume":"114","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lalazar G, Houlihan SL, Tschaharganeh DF, Baslan T, Chen CC, Requena D, Tian S, Bosbach B, Wilkinson JE, Simon SM, Lowe SW. DNAJB1-PRKACA fusion kinase interacts with \u03b2-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2017;114(50):13076\u201384. https:\/\/doi.org\/10.1073\/pnas.1716483114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1610_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001700","author":"AF O\u2019Neill","year":"2026","unstructured":"O\u2019Neill AF, et al. Fibrolamellar Cancer Foundation working group. Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma. Hepatology. 2026. https:\/\/doi.org\/10.1097\/HEP.0000000000001700. (online ahead of print).","journal-title":"Hepatology"},{"key":"1610_CR6","doi-asserted-by":"publisher","first-page":"4246","DOI":"10.1038\/s41591-025-03995-y","volume":"31","author":"M Baretti","year":"2025","unstructured":"Baretti M, Kirk AM, Ladle BH, et al. A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial. Nat Med. 2025;31:4246\u201355. https:\/\/doi.org\/10.1038\/s41591-025-03995-y . ClinicalTrials.gov NCT04248569.","journal-title":"Nat Med"},{"key":"1610_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","volume":"4","author":"C Baethge","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA\u2014a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5. https:\/\/doi.org\/10.1186\/s41073-019-0064-8.","journal-title":"Res Integr Peer Rev"},{"issue":"7","key":"1610_CR8","doi-asserted-by":"publisher","first-page":"102162","DOI":"10.1016\/j.clinre.2023.102162","volume":"47","author":"MM Aloysius","year":"2023","unstructured":"Aloysius MM, et al. Fibrolamellar hepatocellular carcinoma: an epidemiologic and 5-year cancer survival assessment based off SEER data. Clin Res Hepatol Gastroenterol. 2023;47(7):102162. https:\/\/doi.org\/10.1016\/j.clinre.2023.102162.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"16 suppl","key":"1610_CR9","first-page":"e16213","volume":"42","author":"M Adamek","year":"2024","unstructured":"Adamek M, et al. Fibrolamellar hepatocellular carcinoma (FL-HCC) epidemiology, survival characteristics, and outcomes: SEER study. J Clin Oncol. 2024;42(16 suppl):e16213. conference abstract.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1610_CR10","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s11605-016-3216-x","volume":"20","author":"S Yamashita","year":"2016","unstructured":"Yamashita S, Vauthey JN, Kaseb AO, et al. Prognosis of fibrolamellar carcinoma compared to non-cirrhotic conventional hepatocellular carcinoma. J Gastrointest Surg. 2016;20(10):1725\u201331. https:\/\/doi.org\/10.1007\/s11605-016-3216-x.","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"1610_CR11","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/modpathol.2015.4","volume":"28","author":"RP Graham","year":"2015","unstructured":"Graham RP, Jin L, Knutson DL, et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Mod Pathol. 2015;28(6):822\u20139. https:\/\/doi.org\/10.1038\/modpathol.2015.4.","journal-title":"Mod Pathol"},{"issue":"4","key":"1610_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41379-019-0398-2","volume":"33","author":"M Vyas","year":"2020","unstructured":"Vyas M, Hechtman JF, Zhang Y, Benayed R, Yavas A, Askan G, Shia J, Klimstra DS, Basturk O. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Mod Pathol. 2020;33(4):648\u201356. https:\/\/doi.org\/10.1038\/s41379-019-0398-2.","journal-title":"Mod Pathol"},{"issue":"8","key":"1610_CR13","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1097\/PAS.0000000000002259","volume":"48","author":"M Tanaka","year":"2024","unstructured":"Tanaka M, Takeshita K, Kunita A, et al. PRKACA\/PRKACB fusions in pancreatobiliary intraductal oncocytic papillary neoplasms including those with atypical morphology: an analysis of 22 cases expanding morphologic spectrum. Am J Surg Pathol. 2024;48(8):1032\u201340. https:\/\/doi.org\/10.1097\/PAS.0000000000002259.","journal-title":"Am J Surg Pathol"},{"key":"1610_CR14","doi-asserted-by":"publisher","first-page":"10887","DOI":"10.1038\/s41467-024-55238-2","volume":"15","author":"D Requena","year":"2024","unstructured":"Requena D, et al. Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma. Nat Commun. 2024;15:10887. https:\/\/doi.org\/10.1038\/s41467-024-55238-2.","journal-title":"Nat Commun"},{"issue":"16","key":"1610_CR15","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1158\/0008-5472.CAN-23-4110","volume":"84","author":"M Shirani","year":"2024","unstructured":"Shirani M, et al. Increased protein kinase A activity induces fibrolamellar hepatocellular carcinoma features independent of DNAJB1. Cancer Res. 2024;84(16):2626\u201344. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-4110.","journal-title":"Cancer Res"},{"issue":"2","key":"1610_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/XCS.0000000000000476","volume":"236","author":"H Aziz","year":"2023","unstructured":"Aziz H, Brown ZJ, Madani SP, Kamel IR, Pawlik TM. Fibrolamellar hepatocellular carcinoma: comprehensive review of diagnosis, imaging, and management. J Am Coll Surg. 2023;236(2):399\u2013410. https:\/\/doi.org\/10.1097\/XCS.0000000000000476.","journal-title":"J Am Coll Surg"},{"issue":"6","key":"1610_CR17","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.jamcollsurg.2012.08.001","volume":"215","author":"MN Mavros","year":"2012","unstructured":"Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg. 2012;215(6):820\u201330. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2012.08.001.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"1610_CR18","first-page":"3","volume":"6","author":"CS Ang","year":"2013","unstructured":"Ang CS, Kelley RK, Choti MA, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013;6(1):3\u20139.","journal-title":"Gastrointest Cancer Res"},{"issue":"6","key":"1610_CR19","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/cncr.21703","volume":"106","author":"F Stipa","year":"2006","unstructured":"Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106(6):1331\u20138. https:\/\/doi.org\/10.1002\/cncr.21703.","journal-title":"Cancer"},{"issue":"1","key":"1610_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12957-016-0903-8","volume":"14","author":"WT Kassahun","year":"2016","unstructured":"Kassahun WT. Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol. 2016;14(1):151. https:\/\/doi.org\/10.1186\/s12957-016-0903-8.","journal-title":"World J Surg Oncol"},{"issue":"4","key":"1610_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/jso.23658","volume":"110","author":"RT Groeschl","year":"2014","unstructured":"Groeschl RT, et al. Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma. J Surg Oncol. 2014;110(4):412\u20135. https:\/\/doi.org\/10.1002\/jso.23658.","journal-title":"J Surg Oncol"},{"key":"1610_CR22","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/IJGM.S338066","volume":"15","author":"G Polychronidis","year":"2022","unstructured":"Polychronidis G, Feng J, Murtha-Lemekhova A, et al. Factors influencing overall survival for patients with fibrolamellar hepatocellular carcinoma: analysis of the Surveillance, Epidemiology, and End Results database. Int J Gen Med. 2022;15:393\u2013406. https:\/\/doi.org\/10.2147\/IJGM.S338066.","journal-title":"Int J Gen Med"},{"issue":"7","key":"1610_CR23","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.dld.2025.04.016","volume":"57","author":"X Ye-Tran","year":"2025","unstructured":"Ye-Tran X, Bouattour M, Fresneau B, et al. Response to systemic treatments and survival of fibrolamellar carcinomas: an AGEO-SFCE French multicenter retrospective cohort. Dig Liver Dis. 2025;57(7):1495\u2013500. https:\/\/doi.org\/10.1016\/j.dld.2025.04.016.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"1610_CR24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1200\/JCO.2003.10.103","volume":"21","author":"YZ Patt","year":"2003","unstructured":"Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003;21(3):421\u20137. https:\/\/doi.org\/10.1200\/JCO.2003.10.103.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1610_CR25","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.3390\/cancers14215347","volume":"14","author":"KY Chen","year":"2022","unstructured":"Chen KY, Popovic A, Hsiehchen D, Baretti M, Griffith P, et al. Clinical outcomes in fibrolamellar hepatocellular carcinoma treated with immune checkpoint inhibitors. Cancers (Basel). 2022;14(21):5347. https:\/\/doi.org\/10.3390\/cancers14215347.","journal-title":"Cancers (Basel)"},{"key":"1610_CR26","doi-asserted-by":"publisher","first-page":"1367450","DOI":"10.3389\/fonc.2024.1367450","volume":"14","author":"C Hackenbruch","year":"2024","unstructured":"Hackenbruch C, et al. FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion. Front Oncol. 2024;14:1367450. https:\/\/doi.org\/10.3389\/fonc.2024.1367450.","journal-title":"Front Oncol"},{"issue":"12","key":"1610_CR27","doi-asserted-by":"publisher","first-page":"e005620","DOI":"10.1136\/jitc-2022-005620","volume":"10","author":"R Berger","year":"2022","unstructured":"Berger R, Dinstag G, Tirosh O, et al. Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab. J Immunother Cancer. 2022;10(12):e005620. https:\/\/doi.org\/10.1136\/jitc-2022-005620.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1610_CR28","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.1038\/s41467-022-33746-3","volume":"13","author":"J Bauer","year":"2022","unstructured":"Bauer J, K\u00f6hler N, Maringer Y, et al. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun. 2022;13(1):6401. https:\/\/doi.org\/10.1038\/s41467-022-33746-3.","journal-title":"Nat Commun"},{"issue":"3","key":"1610_CR29","doi-asserted-by":"publisher","first-page":"101469","DOI":"10.1016\/j.xcrm.2024.101469","volume":"5","author":"AM Kirk","year":"2024","unstructured":"Kirk AM, Crawford JC, Chou CH, et al. DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell Rep Med. 2024;5(3):101469. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101469.","journal-title":"Cell Rep Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01610-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01610-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:03:35Z","timestamp":1791068615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01610-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01610-y","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics committee approval and informed consent were not required for this review article, as it did not involve human participants, interventions, or the use of identifiable patient data.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"233"}}